Tesamorelin Q3 2026: what changed

This article is educational and does not constitute medical advice. Nothing here should be read as a recommendation to use, source, or dose tesamorelin. Consult a qualified healthcare provider before considering any peptide or hormone-related intervention.

In Q3 2026, the published literature on tesamorelin moved on two separate tracks. The approved indication, HIV-associated lipodystrophy, received its first pooled meta-analysis and a new randomised trial protocol. Off that track, a pilot study reported tentative brain-connectivity signals in adults with mild cognitive impairment, generating commentary without yet generating conclusions. Regulatory status and WADA doping classification are unchanged.

What changed this quarter

The most substantive new entry is a systematic review and meta-analysis by Ditta and colleagues published on July 31, 2026 in the Journal of the International Association of Providers of AIDS Care^[1]. Pooling four randomised controlled trials and 909 participants, the analysis found that tesamorelin 2 mg daily produced a mean reduction in visceral adipose tissue of 21.47 units, a waist-circumference reduction of 1.61 cm, and a trunk-fat reduction of 1.20 kg, with lean mass increasing by 1.42 kg. Total cholesterol showed a modest improvement. The authors documented growth-hormone-related adverse effects and higher discontinuation rates in the active arms and stated that limited data on long-term safety, optimal dosing, and durability of treatment effects warrant caution.

The Ditta meta-analysis is the first pooled quantification of the effect sizes across the approved indication's entire trial base. The finding that visceral fat reduction is real and measurable is not new, the phase-3 trials that formed the FDA approval dossier already established that, but placing the four trials in a single quantitative frame gives prescribers a cleaner summary of the expected effect magnitude than any single trial could. The label specifies a daily 2 mg subcutaneous injection for reduction of excess abdominal fat in HIV-infected adults with lipodystrophy^[2], and the Ditta pooled estimate tracks closely with the pivotal-trial data the label is built on.

Limited data on long-term safety, optimal dosing strategies, and durability of treatment effects warrant caution.

A new trial protocol: tesamorelin plus exercise in frail older adults with HIV

On July 8, 2026 Erlandson and colleagues at the University of Colorado published a two-site, double-blind, randomised trial protocol in BMJ Open^[3]. The TRIUMPH trial (not to be confused with the retatrutide programme sharing the same acronym) will enrol 100 sedentary older adults aged 50 to 80 years who are living with HIV, are frail or at risk for frailty, and have excess abdominal adiposity. Participants will receive either tesamorelin or placebo alongside a home-based semisupervised exercise programme for 24 weeks, then continue independent exercise for a further 24 weeks.

Primary endpoints at weeks 24 and 48 are physical function, muscle content and quality, quality of life, and exercise adherence. Secondary endpoints include mitochondrial function. The trial is registered as NCT06554717. Frailty in adults with HIV is an under-researched area: antiretroviral therapy has converted HIV into a chronic condition managed over decades, and the interaction between age-related sarcopenia and the lipodystrophy pattern that tesamorelin targets is precisely the kind of question that single-indication approval programmes leave unanswered. This trial protocol does not yet yield results, but it marks a broadening of the clinical question being formally asked of the compound beyond simple visceral-fat reduction toward the question of whether tesamorelin can contribute to physical function and quality of life in an ageing HIV population.

The brain-connectivity signal: promising, not conclusive

On June 17, 2026 Stewart and colleagues from the University of Texas Medical Branch and Houston Methodist published a double-blind, placebo-controlled pilot trial in eNeurologicalSci^[4]. Twenty-two subjects with baseline cognition ranging from normal to mild cognitive impairment received either low-dose tesamorelin (1 mg) or placebo for 10 weeks. The primary result was that low-dose treatment was not directly linked with significant changes in the study's measured outcomes across body composition, fatigue, sleep, physical performance, or glucose tolerance.

Where the paper becomes more interesting is in the secondary analysis. Using machine-learning models on neuroimaging data, the authors identified potential treatment-related differences in areas of the brain related to cognitive function, specifically the right anterior cingulate cortex and the left superior frontal occipital fasciculus. The team's conclusion was careful: the pilot study highlights the potential benefits of pairing cognitive tests and neuroimaging with machine-learning tools to achieve greater sensitivity for treatment-related effects. That framing is appropriate for an n=22 pilot. The ML finding is a signal worth designing a larger study around, not a basis for clinical inference.

Two caveats are load-bearing here. First, the 1 mg dose tested is below the 2 mg FDA-approved dose for lipodystrophy. Whether the neuroimaging signal, if real, scales with dose is unknown. Second, none of the 22 subjects had HIV. This is a non-approved-indication study in a healthy-to-mildly-impaired population, and the results are not transferable to the approved indication or to each other without caution.

Regulatory and doping status: unchanged

Tesamorelin's regulatory status across the site's coverage area is unchanged from Q2. In the United States, Egrifta and Egrifta SV (Theratechnologies) remain the only authorised forms, indicated for reduction of excess abdominal fat in HIV-infected adults with lipodystrophy. The Egrifta SV label was revised in February 2024 and published on DailyMed in July 2026^[2]. The European marketing-authorisation application, withdrawn in 2012, has not been re-submitted. There is no authorised tesamorelin product in the EU, EEA, or UK. Lawful access in those jurisdictions runs only through unlicensed-medicine or named-patient routes that a prescribing clinician requests and takes responsibility for; general or online sale to the public is not lawful.

In anti-doping, the 2026 WADA Prohibited List continues to capture tesamorelin under S2 as a GHRH-releasing-factor analogue, prohibited both in and out of competition for athletes subject to the WADA Code. A 2026 sports-medicine review by Villegas Meza and colleagues in the Journal of Bone and Joint Surgery Reviews^[5] confirmed that the detection science for GHRH analogues, including tesamorelin, has advanced materially since Memdouh and colleagues published validated liquid-chromatography tandem-mass-spectrometry methods in 2021. Competing athletes should treat S2 capture as a straightforward disqualification risk.

Where this lands

At the start of Q3 2026, tesamorelin sits in an unusual position among the peptides in this library. It has something the others lack: a completed FDA approval with a defined indication, a labelled dose, a characterised safety profile, and a meta-analysis now confirming the pooled effect size. What it does not have is evidence for the off-label uses most commonly discussed online: anti-ageing, body-composition improvement in non-HIV individuals, sleep quality, or cognitive enhancement. The brain-connectivity pilot from Stewart and colleagues is the closest thing to a published study on the cognitive question, and its own authors describe it as an n=22 pilot in search of a larger trial. The Erlandson TRIUMPH protocol is pushing the evidence base forward on physical function in ageing, but it has not yet read out.

The Ditta meta-analysis and the Stewart pilot together form the most current published picture. Both reward careful reading rather than headline extraction. Readers looking for the full regulatory and mechanism-of-action context should start with the tesamorelin peptide page, which contains the approved-indication timeline, the EU withdrawal history, the country-by-country access situation, and the sourcing accountability notes.